Utilization of well characterized cohort studies and clinical trials to conduct ancillary scientific studies on pathophysiology, responses to treatment, and identify new ways to predict and treat disease. Restore the Ancillary Studies mechanism. Improved biobanks and data sharing platforms are needed. Facilitate public-private partnerships.
Investigators need NHLBI support for programs that transform our approach to heart valve disease to mechanism-based prevention with large-animal preclinical studies through: an NHLBI-sponsored sponsored Heart Valve Network; development of models of genetic and acquired valve disease; a study section devoted to valve disease; and RFAs and RFPs based on Task Force priorities in mitral valve disease.
Most Pharmacological interventions in cardiovascular diseases tend to address to be used in palliative manner and chronically. There is urgent need for treatments that are curative. This goes to identifying molecular drivers of the diseases and targeting them to correct the underlying pathophysiology rather than symptom suppression.
What is the impact of age, gender, and comorbidities on pathophysiology and treatment of total body ischemia and reperfusion, and how should therapies be modified accordingly?